An interventional study of Nanotechnology Structured water Magnalife and Trimethoprim in Recurrent Urinary Tract Infection, sponsored by University of Sulaimani. Completed at 1 site in Iraq. Open to female participants aged 24 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-17.
Sponsored by University of Sulaimani · Not applicable, Interventional, and Prevention
This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.
This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.
Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.
In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.
6,686 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 437 is above the median of 120 across 4,199 interventional studies indexed under Infections.
Browse Infections studies →University of Sulaimani is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The group of patients given nanotechnology structured water magnalife
Dietary Supplement: Nanotechnology Structured water Magnalife
The group of patients given Trimethoprim
Drug: Trimethoprim
The group of patients given ordinary bottled drinking water
Dietary Supplement: Ordinary bottled drinking water
Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
Also known as: Magnalife, 5200250040466
Antibiotic
Also known as: Proloprim
Placebo
Recurrent Urinary Tract Infection
Urinalysis by GUE (\>10 white blood cells (WBC)/mm3 per high-power field (HPF) Urine culture (urinary pathogen of ≥105 colony-forming units (CFU) per mL)
Time frame: Twelve months
Time to first recurrent UTI
The time since the beginning of the study until the first recurrent UTI (days)
Time frame: Twelve months
Plan to share: No — The duration of illness, number of recurrence of UTI, other co-morbid diseases
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sulaimani